Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Stryker (SYK) Delivers 7.7% Sales Growth in Q3 but Lowers Full-Year Outlook

Stryker (SYK) Delivers 7.7% Sales Growth in Q3 but Lowers Full-Year Outlook

Key Takeaways

  • Stryker reported third quarter 2026 net sales of $6.52 billion, up 7.7% year over year, but below the analyst consensus of roughly $6.62 billion.
  • Adjusted EPS came in at $3.52, up 10.3% from a year ago, narrowly missing the $3.55 consensus estimate.
  • Reported GAAP diluted EPS fell 11.7% to $1.96, pressured by higher expenses and special charges.
  • Management lowered its full-year 2026 outlook, citing softer hip and knee procedure trends and lingering supply constraints.
  • MedSurg and Neurotechnology sales grew 9.2%, while the Orthopaedics segment rose a more modest 5.7%.
  • Shares slid about 7.6% in after-hours trading following the release.

Earnings Context and Why It Matters

Stryker stands as one of the largest medical technology companies globally, holding leading positions in orthopedics, medical and surgical equipment, and neurotechnology. Its quarterly results offer a useful gauge of elective procedure demand, hospital capital spending, and overall healthcare activity. The third quarter of 2026 held particular interest given the company’s earlier cyberattack and systems rollout in its orthopedics businesses. I also checked this using Tickeron’s AI Screener to see how SYK compares with peers in the space. Investors were looking to see if robust capital-equipment demand could counter softer trends in joint replacements. The results, along with the reduced full-year guidance, point to how procedure volumes and affordability issues are influencing the medical device sector as we head into 2027.

Reported Results

For the quarter ended September 30, 2026, SYK posted net sales of $6.52 billion, a 7.7% rise from $6.06 billion a year earlier. Organic sales growth also reached 7.7%. The figure landed below the roughly $6.62 billion consensus. Reported net earnings declined 12.3% to $753 million, producing diluted EPS of $1.96 versus $2.22 previously. Adjusted EPS, which excludes one-time items, rose 10.3% to $3.52 and came in just under the $3.55 analyst target. Segment performance showed MedSurg and Neurotechnology advancing 9.2%, while Orthopaedics increased 5.7%. Adjusted operating margin expanded 60 basis points to 26.2%, though the reported margin slipped to 15.9% from 18.7%. Management trimmed its full-year outlook to organic sales growth of 6.5% to 7% and adjusted EPS of $14.80 to $14.90.

Market Reaction and Investor Sentiment

The market responded negatively to the revenue and EPS shortfalls combined with the lowered guidance. SYK shares dropped roughly 7.6% in after-hours trading to around $288. The reaction reflected disappointment in both the headline numbers and management’s comments on slowing hip and knee procedures, with CEO Kevin Lobo noting that results “fell short of our expectations.” While adjusted earnings growth and margin improvement showed operational strength, the softer demand outlook carried more weight for investors.

Forward Outlook and Key Factors to Monitor

Going forward, attention will center on whether the softer hip and knee procedure environment stabilizes. Management linked the slowdown to affordability pressures from higher insurance premiums and deductibles, plus more pre-authorization denials. Supply normalization in the peripheral vascular business remains another focus, with a full recovery expected by year-end. The company is also working to improve execution around its Mako robotics platform and new product launches after earlier disruptions. On a more positive note, capital-equipment demand stays strong, with a solid order book and double-digit growth in areas such as Endoscopy and OrthoTech. SYK repurchased $1 billion of shares in the quarter and gained authorization for another $3 billion. Management anticipates solid fourth-quarter results and momentum into 2027, though formal guidance will come early next year. Procedure trends, supply recovery, and margin execution will stay the main items to watch.

Using AI Tools to Track Medical Device Stocks

In my ongoing review of names like SYK, I find Tickeron’s AI Screener helpful for quickly comparing fundamentals, technical patterns, and peer performance across the medical device sector. It surfaces relevant ideas without requiring hours of manual work and helps keep my watchlist focused on the factors that matter most after earnings releases.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SYK

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for SYK turns negative, indicating new downward trend

SYK saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 52 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 58%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 20 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 53%.

The Moving Average Convergence Divergence Histogram (MACD) for SYK turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 22 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Following a +2.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 178 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

The Aroon Indicator entered an Uptrend today. In 133 of 256 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of reconstructive, medical and surgical, and neurotechnology and spine products

Industry MedicalNursingServices

Industry
Medical Specialties
Address
1941 Stryker Way
Phone
+1 269 385-2600
Employees
56000
Web
https://www.stryker.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.